Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

Scemblix and Fabhalta – demonstrates our leadership in both solid tumors and hematologic diseases,” said Shreeram Aradhye, M.D., president, development and chief medical officer, Novartis. “At ASCO ...

A federal judge partly sided with HHS over its decision to not approve proposals from Bristol Myers Squibb Co., Novartis AG, Eli Lilly & Co., and Sanofi SA that would dramatically change how they ...

There are already four approved therapies to treat IgAn — Novartis' Fabhalta — $129m revenues in 2024, Calliditas Therapeutics Tarpeyo — ~$150m revenues, and Travere Therapeutics (TVTX ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by gene therapies such as Sarepta Therapeutics’ Elevidys and Novartis ...

Novartis announced plans to acquire Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company developing medicines targeting microRNAs, for $800 million. The all cash deal includes a ...